LYMPHANGIOLEIOMYOMATOSIS (LAM)
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS (LAM) explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS (LAM) trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS (LAM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a leukemia drug help treat rare lung disease LAM? new trial launches
Disease control Recruiting nowThis phase 1 trial is testing the long-term safety of imatinib (Gleevec), a drug already approved for leukemia, in 20 women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Participants will take either imatinib or a placebo twice daily for 6 months, with regular …
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could blood particles reveal secrets of rare lung disease LAM?
Knowledge-focused Recruiting nowThis study looks at tiny particles called extracellular vesicles in the blood of women with a rare lung disease called LAM. Researchers want to see if these particles can act as biomarkers to show how the lungs are affected. The study will compare women with different forms of LA…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC